Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure

Overview

Journal J Card Fail

Specialty Cardiology & Vascular Diseases

Date 2016 Jan 2

PMID 26721774

Citations 9

Authors

Ibrahim N Mansour

Adam P Bress

Vicki Groo

Sahar Ismail

Grace Wu

Shitalben R Patel

Julio D Duarte

Rick A Kittles

Thomas D Stamos

Larisa H Cavallari

Affiliations

Soon will be listed here.

Abstract

Background: Procollagen type III N-terminal peptide (PIIINP) is a biomarker of cardiac fibrosis that is associated with heart failure prognosis in whites. Its prognostic significance in African Americans is unknown. We sought to determine whether PIIINP is associated with outcomes in African Americans with heart failure.

Methods And Results: Blood was collected from 138 African Americans with heart failure for determining PIIINP and genetic ancestry, and patients were followed prospectively for death or hospitalization for heart failure. PIIINP was inversely correlated with West African ancestry (R(2) = 0.061; P = .010). PIIINP > 4.88 ng/mL was associated with all-cause mortality on univariate (hazard ratio [HR] 4.9, 95% confidence interval [CI] 2.2-11.0; P < .001) and multivariate (HR 5.8; 95% CI 1.9-17.3; P = .002) analyses over a median follow-up period of 3 years. We also observed an increased risk for the combined outcome of all-cause mortality or hospitalization for heart failure with PIIINP > 4.88 ng/mL on univariate (HR 2.6, 95% CI 1.6-5.0; P < .001) and multivariate (HR 2.4, 95% CI 1.2-4.7; P = .016) analyses.

Conclusions: High circulating PIIINP is associated with poor outcomes in African Americans with chronic heart failure, suggesting that PIIINP may be useful in identifying African Americans who may benefit from additional therapy to combat fibrosis as a means of improving prognosis.

Citing Articles

The Role of Oxidative Stress and Inflammatory Parameters in Heart Failure.

Wrobel-Nowicka K, Wojciechowska C, Jachec W, Zalewska M, Romuk E Medicina (Kaunas). 2024; 60(5).

PMID: 38792942 PMC: 11123446. DOI: 10.3390/medicina60050760.

Frailty and heart failure: State-of-the-art review.

Talha K, Pandey A, Fudim M, Butler J, Anker S, Khan M J Cachexia Sarcopenia Muscle. 2023; 14(5):1959-1972.

PMID: 37586848 PMC: 10570089. DOI: 10.1002/jcsm.13306.

Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature?.

Sato R, Vatic M, da Fonseca G, von Haehling S Curr Heart Fail Rep. 2022; 19(6):400-411.

PMID: 36261756 PMC: 9653351. DOI: 10.1007/s11897-022-00575-w.

NR3C2 genotype is associated with response to spironolactone in diastolic heart failure patients from the Aldo-DHF trial.

Dumeny L, Vardeny O, Edelmann F, Pieske B, Duarte J, Cavallari L Pharmacotherapy. 2021; 41(12):978-987.

PMID: 34569641 PMC: 8688239. DOI: 10.1002/phar.2626.

Cox-sMBPLS: An Algorithm for Disease Survival Prediction and Multi-Omics Module Discovery Incorporating -Regulatory Quantitative Effects.

Vahabi N, McDonough C, Desai A, Cavallari L, Duarte J, Michailidis G Front Genet. 2021; 12:701405.

PMID: 34408773 PMC: 8366414. DOI: 10.3389/fgene.2021.701405.

References

Brilla C, Funck R, Rupp H . Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000; 102(12):1388-93. DOI: 10.1161/01.cir.102.12.1388. View

Zannad F, Alla F, Dousset B, Perez A, Pitt B . Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000; 102(22):2700-6. DOI: 10.1161/01.cir.102.22.2700. View

Tsutsui H, Matsushima S, Kinugawa S, Ide T, Inoue N, Ohta Y . Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart. Hypertens Res. 2007; 30(5):439-49. DOI: 10.1291/hypres.30.439. View

Falush D, Stephens M, Pritchard J . Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics. 2003; 164(4):1567-87. PMC: 1462648. DOI: 10.1093/genetics/164.4.1567. View

Zannad F, McMurray J, Krum H, Van Veldhuisen D, Swedberg K, Shi H . Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2010; 364(1):11-21. DOI: 10.1056/NEJMoa1009492. View

Brown D, Haldeman G, Croft J, Giles W, Mensah G . Racial or ethnic differences in hospitalization for heart failure among elderly adults: Medicare, 1990 to 2000. Am Heart J. 2005; 150(3):448-54. DOI: 10.1016/j.ahj.2004.11.010. View

Moe G, Tu J . Heart failure in the ethnic minorities. Curr Opin Cardiol. 2009; 25(2):124-30. DOI: 10.1097/HCO.0b013e328335fea4. View

Pritchard J, Stephens M, Donnelly P . Inference of population structure using multilocus genotype data. Genetics. 2000; 155(2):945-59. PMC: 1461096. DOI: 10.1093/genetics/155.2.945. View

Kobayashi M, Machida N, Mitsuishi M, Yamane Y . Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure. Am J Hypertens. 2004; 17(12 Pt 1):1112-9. DOI: 10.1016/j.amjhyper.2004.07.007. View

10.

Bahrami H, Kronmal R, Bluemke D, Olson J, Shea S, Liu K . Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med. 2008; 168(19):2138-45. PMC: 3038918. DOI: 10.1001/archinte.168.19.2138. View

11.

Klappacher G, Franzen P, HaaB D, Mehrabi M, Binder M, Plesch K . Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995; 75(14):913-8. DOI: 10.1016/s0002-9149(99)80686-9. View

12.

Radauceanu A, Ducki C, Virion J, Rossignol P, Mallat Z, McMurray J . Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure. J Card Fail. 2008; 14(6):467-74. DOI: 10.1016/j.cardfail.2008.02.014. View

13.

Rossignol P, Dobre D, McMurray J, Swedberg K, Krum H, Van Veldhuisen D . Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy:.... Circ Heart Fail. 2013; 7(1):51-8. DOI: 10.1161/CIRCHEARTFAILURE.113.000792. View

14.

Kosoy R, Nassir R, Tian C, White P, Butler L, Silva G . Ancestry informative marker sets for determining continental origin and admixture proportions in common populations in America. Hum Mutat. 2008; 30(1):69-78. PMC: 3073397. DOI: 10.1002/humu.20822. View

15.

Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B . Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348(14):1309-21. DOI: 10.1056/NEJMoa030207. View

16.

Weber K, Brilla C, Campbell S, Guarda E, Zhou G, Sriram K . Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol. 1993; 88 Suppl 1:107-24. DOI: 10.1007/978-3-642-72497-8_8. View

17.

Krantz M, Ambardekar A, Kaltenbach L, Hernandez A, Heidenreich P, Fonarow G . Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure). Am J Cardiol. 2011; 107(12):1818-23. DOI: 10.1016/j.amjcard.2011.02.322. View

18.

Packer M, Bristow M, Cohn J, Colucci W, Fowler M, Gilbert E . The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996; 334(21):1349-55. DOI: 10.1056/NEJM199605233342101. View

19.

Juurlink D, Mamdani M, Lee D, Kopp A, Austin P, Laupacis A . Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351(6):543-51. DOI: 10.1056/NEJMoa040135. View

20.

Tian C, Hinds D, Shigeta R, Kittles R, Ballinger D, Seldin M . A genomewide single-nucleotide-polymorphism panel with high ancestry information for African American admixture mapping. Am J Hum Genet. 2006; 79(4):640-9. PMC: 1592561. DOI: 10.1086/507954. View